Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Quantifying mutant huntingtin protein in human cerebrospinal fluid to support the development of huntingtin-lowering therapies

Open access

Abstract

Huntington’s disease (HD) is caused by a cytosine adenine guanine-repeat expansion in the huntingtin gene. This results in the production of toxic mutant huntingtin protein (mHTT), which has an elongated polyglutamine (polyQ) stretch near the protein’s N-terminal end. The pharmacological lowering of mHTT expression in the brain targets the underlying driver of HD and is one of the principal therapeutic strategies being pursued to slow or stop disease progression. This report describes the characterisation and validation of an assay designed to quantify mHTT in the cerebrospinal fluid of individuals with HD, for use in registrational clinical trials. The assay was optimised, and its performance was characterised with recombinant huntingtin protein (HTT) varying in overall and polyQ-repeat length. The assay was successfully validated by two independent laboratories in regulated bioanalytical environments and showed a steep signal increase as the polyQ stretch of recombinant HTTs pivoted from wild-type to mutant protein forms. Linear mixed effects modelling confirmed highly parallel concentration–response curves for HTTs, with only a minor impact of individual slopes of the concentration–response for different HTTs (typically < 5% of the overall slope). This implies an equivalent quantitative signal behaviour for HTTs with differing polyQ-repeat lengths. The reported method may be a reliable biomarker tool with relevance across the spectrum of HD mutations, which can facilitate the clinical development of HTT-lowering therapies in HD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-023-32630-4

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 mHTT bead-based ligand binding assay: capture and detection of antibody-binding regions. mHTT, mutant huntingtin protein; polyQ, polyglutamine.
Figure 1 mHTT bead-based ligand binding assay: capture and detection of antibody-binding regions. mHTT, mutant huntingtin protein; polyQ, polyglutamine.CC BY · PubMed Central
Figure 2 Concentration–response of different recombinant HTT. (a) Normalised signals across recombinant proteins varying in the number of polyQ repeats (12 repeats tested) and overall protein size (three sizes tested). The number of polyQ repeats is indicated by colour while overall protein size is indicated by marker symbols. The Q45 protein was measured across all eight plates and the highest concentration was used to derive a normalisation factor applied to all concentration-responses on the plate for cross-plate comparability. The error bars for the Q45 protein reflect the standard deviation across all eight runs. The Q46 medium size fragment was chosen as the reference protein during assay validation; both representative concentration-responses depicted in the figure were measured separately. (b) All individual concentration-responses of the Q45 protein measured across different plates. Note that normalisation induced the identical response at the highest concentration. (c) Normalised signals for fragment and full-length versions of proteins with the same polyQ repeat numbers and similar molarity. The same colour coding as for (a) was used to label the different polyQ repeat numbers. HD, Huntington’s disease; HTT, huntingtin protein; norm., normalisation; polyQ, polyglutamine.
Figure 2 Concentration–response of different recombinant HTT. (a) Normalised signals across recombinant proteins varying in the number of polyQ repeats (12 repeats tested) and overall protein size (three sizes tested). The number of polyQ repeats is indicated by colour while overall protein size is indicated by marker symbols. The Q45 protein was measured across all eight plates and the highest concentration was used to derive a normalisation factor applied to all concentration-responses on the plate for cross-plate comparability. The error bars for the Q45 protein reflect the standard deviation across all eight runs. The Q46 medium size fragment was chosen as the reference protein during assay validation; both representative concentration-responses depicted in the figure were measured separately. (b) All individual concentration-responses of the Q45 protein measured across different plates. Note that normalisation induced the identical response at the highest concentration. (c) Normalised signals for fragment and full-length versions of proteins with the same polyQ repeat numbers and similar molarity. The same colour coding as for (a) was used to label the different polyQ repeat numbers. HD, Huntington’s disease; HTT, huntingtin protein; norm., normalisation; polyQ, polyglutamine.CC BY · PubMed Central
Figure 3 Model predictions of the Offset and Offset + Slope models across all concentration–response curves. (a) The Offset model was defined by random intercepts and fixed slopes. (b) The Offset + Slope model was defined by random intercepts and random slopes. In (a) and (b), the legend indicates each recombinant HTTs’ polyQ-repeat length, overall length and plate number, respectively. Legends in (a) and (b) indicate each recombinant HTTs’ polyQ-repeat length (first number) and protein size/number of amino acids (second number). (c) Comparison of predicted signals from the models in (a) and (b). Legend in (c) indicates the recombinant HTTs: icon shape denotes the protein size/number of amino acids; icon colour denotes the polyQ-repeat length. HTT, huntingtin protein; norm., normalisation; polyQ, polyglutamine.
Figure 3 Model predictions of the Offset and Offset + Slope models across all concentration–response curves. (a) The Offset model was defined by random intercepts and fixed slopes. (b) The Offset + Slope model was defined by random intercepts and random slopes. In (a) and (b), the legend indicates each recombinant HTTs’ polyQ-repeat length, overall length and plate number, respectively. Legends in (a) and (b) indicate each recombinant HTTs’ polyQ-repeat length (first number) and protein size/number of amino acids (second number). (c) Comparison of predicted signals from the models in (a) and (b). Legend in (c) indicates the recombinant HTTs: icon shape denotes the protein size/number of amino acids; icon colour denotes the polyQ-repeat length. HTT, huntingtin protein; norm., normalisation; polyQ, polyglutamine.CC BY · PubMed Central
Figure 4 Relationship between polyQ-repeat length of recombinant HTTs and random slopes. Legends indicate the recombinant HTTs: icon shape denotes the protein size/number of amino acids; icon colour denotes the polyQ-repeat length. HTT, huntingtin protein; polyQ, polyglutamine.
Figure 4 Relationship between polyQ-repeat length of recombinant HTTs and random slopes. Legends indicate the recombinant HTTs: icon shape denotes the protein size/number of amino acids; icon colour denotes the polyQ-repeat length. HTT, huntingtin protein; polyQ, polyglutamine.CC BY · PubMed Central
Figure 5 Simulation of longitudinal signals with an HTT-lowering effect. Two signal levels were used to simulate visits at baseline (Log signal = 1) and at follow-up (Log signal = 0.7), respectively. (a) The Offset model was defined by the random intercepts and fixed slopes that emerged from the Offset model fit to the concentration–response curve data. (b) Percent change plotted against absolute change in the Offset model. (c) The Offset + Slope model was defined by the random intercepts and random slopes that emerged from the Offset + Slope model fit to the concentration–response curve data. (d) Percent change plotted against absolute change in the Offset + Slope model. Legends outline the recombinant HTTs: icon shape denotes the protein size/number of amino acids; icon colour denotes the polyQ-repeat length. BL, baseline; FU, follow-up; HTT, huntingtin protein; polyQ, polyglutamine.
Figure 5 Simulation of longitudinal signals with an HTT-lowering effect. Two signal levels were used to simulate visits at baseline (Log signal = 1) and at follow-up (Log signal = 0.7), respectively. (a) The Offset model was defined by the random intercepts and fixed slopes that emerged from the Offset model fit to the concentration–response curve data. (b) Percent change plotted against absolute change in the Offset model. (c) The Offset + Slope model was defined by the random intercepts and random slopes that emerged from the Offset + Slope model fit to the concentration–response curve data. (d) Percent change plotted against absolute change in the Offset + Slope model. Legends outline the recombinant HTTs: icon shape denotes the protein size/number of amino acids; icon colour denotes the polyQ-repeat length. BL, baseline; FU, follow-up; HTT, huntingtin protein; polyQ, polyglutamine.CC BY · PubMed Central
Figure 6 Variability of the estimated percent change signal in mHTT concentrations across recombinant proteins. Percent change from baseline for each recombinant HTT plotted against mean percent change from baseline across proteins. Legends indicate the recombinant HTTs: icon shape denotes the protein size (number of amino acids); icon colour denotes the polyQ-repeat length. HTT, huntingtin protein; mHTT, mutant HTT; polyQ, polyglutamine.
Figure 6 Variability of the estimated percent change signal in mHTT concentrations across recombinant proteins. Percent change from baseline for each recombinant HTT plotted against mean percent change from baseline across proteins. Legends indicate the recombinant HTTs: icon shape denotes the protein size (number of amino acids); icon colour denotes the polyQ-repeat length. HTT, huntingtin protein; mHTT, mutant HTT; polyQ, polyglutamine.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 14

Metadata

Authors
Vauleon, S., Schutz, K., Massonnet, B., Gruben, N., Manchester, M., Buehler, A., Schick, E., Boak, L., & Hawellek, D. J.
Affiliations
F. Hoffmann-La Roche AG (CH)
Corresponding author
Hawellek, David J.
Venue
Scientific Reports
Published
2023-04-01
Volume
13
Issue
1
Pages
5332-5332
ISSN
2045-2322 (ISSN-L)
OpenAlex
W4362520610
Cited by
14
References
26
Citations by year
2026: 6 · 2025: 5 · 2024: 3
FWCI
1.69
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • medRxiv (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
F. Hoffmann-La Roche Ltd
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
Huntington's disease, mutant huntingtin, cerebrospinal fluid, polyglutamine expansion, biomarker quantification, assay validation, concentration-response curves, CAG repeat expansion
MeSH terms
Huntingtin Protein, Humans, Huntington Disease, Recombinant Proteins, Biomarkers, Mutant Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Quantifying mutant huntingtin protein in human cerebrospinal fluid to support the development of huntingtin-lowering therapies. https://app.cochat.ai/papers/10.1038/s41598-023-32630-4
The paper
Vauleon, S., Schutz, K., Massonnet, B., Gruben, N., Manchester, M., Buehler, A., Schick, E., Boak, L., & Hawellek, D. J. (2023). Quantifying mutant huntingtin protein in human cerebrospinal fluid to support the development of huntingtin-lowering therapies. Scientific Reports. https://doi.org/10.1038/s41598-023-32630-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.